MEDIMMUNE RESPIGAM CANDIDATES IDENTIFIED BY PRUDENTIAL IN PULL-THROUGH PROGRAM; AVAILABLE RESPIGAM MEETS ONLY 40% OF DEMAND; FOLLOW-ON PRODUCT IN PHASE III
Executive Summary
Prudential is identifying infants who fit labeling criteria for use of MedImmune's RespiGam and providing the names of their physicians to the company, MedImmune Director-Managed Care Stephen Collins told a Biotechnology Industry Organization meeting Feb. 11 in Washington, D.C.